// App-Quantinova.ai

: Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Researchers

Presenter

  • Anne Segolene Cottereau

Principal Investigators

  • Louis Rebaud

  • Judith Trotman

  • Pierre Feugier

  • Loretta J. Nastoupil

  • Emmanuel Bachy

  • Ian W. Flinn

  • Corinne Haioun

  • Loic Ysebaert

  • Nancy L. Bartlett

  • Herve Tilly

  • Rene-Olivier Casasnovas

  • Romain Ricci

  • Cedric Portugues

  • Irène Buvat

  • Michel Meignan

  • Franck Morschhauser

Medical Centers

  • LYSA, Paris, France

  • LYSARC, The Lymphoma Academic Research Organisation, Créteil, FRA

  • LITO laboratory, UMR Inserm, Institut Curie, University Paris Saclayr, Orsay, France

  • Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

  • Department of Haematology, Concord Hospital, Concord, Australia

  • Centre Henri BECQUEREL, Rouen, France

  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

  • Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre Benite, France

  • Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Nuclear Medicine, Cochin University Hospital, AP-HP, Paris, France

  • Lymphoid Malignancies Department, Henri Mondor University Hospital/Assistance Publique-Hôpitaux de Paris (AP-HP)/Université Paris-Est Créteil (UPEC), Creteil, France

  • CHU de Henri Mondor, Créteil, France

  • Service des Maladies du Sang, CHU Lille, Lille, France

  • Laboratoire D'Imagerie Translationnelle En Oncologie, Institut Curie, U Inserm, Paris, FRA

  • Hematology Department, University Hospital of Nancy, Vandoeuvre, France

  • Centre Hospitalier Lyon-Sud, LYSARC, The Lymphoma Academic Research Organisation, Lyon, France

  • Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France

Locations

  • France

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved